Since our founding in 2010, CGT Global has pursued our mission to transform healthcare as we accelerate cell and gene therapy research and clinical trials, streamline the commercialization of new treatments, and map the last mile to patient access to these life-changing remedies. By innovating each stage in the cycle; development, commercialization, and delivery, we reduce the overall cost of the care and multiply access points so that millions can receive cutting edge, life-saving gene and cell therapies.

Description
Mononuclear cells (MNCs)are composed of lymphocytes (T cells, B cells, and NK cells), monocytes, dendritic cells, and stem/progenitor cells. These cells are critical components of the immune system and play key roles in the humoral and cell-mediated immune responses. Mononuclear cells are commonly used in research and clinical applications in the areas of immunology, infectious disease, hematological malignancies, vaccine development, transplant therapy, and high-throughput screening.
Mononuclear cells are separated from umbilical cord blood by means of a density gradient centrifugation protocol. Human cord blood CD34 depleted mononuclear cells are isolated from the mononuclear cell fraction by removing the CD34+ population by immunomagnetic separation. The CD34 depleted mononuclear cells contain less than 0.1% CD34+ cells. The presence of CD34+ cells is assessed by flow cytometry prior to cryopreservation. The isolated MNCs can be used to isolate subpopulations or used as a control for donor matched CD34+ stem cell experiments (Please request the CD34 depleted flow-through fraction upon ordering CD34+ stem cells).
Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols.
Additional information
Anticoagulant | |
---|---|
Format | |
Grade | |
Species | |
Cell and Tissue Source | |
Disease State | |
Donor Attributes |